Septerna, Inc. (SEPN)
| Market Cap | 898.86M |
| Revenue (ttm) | 838,000 |
| Net Income (ttm) | -10.27M |
| Shares Out | 42.00M |
| EPS (ttm) | -4.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,245,366 |
| Open | 23.50 |
| IPO Price | 18.00 |
| Day's Range | 20.90 - 25.56 |
| 52-Week Range | 20.90 - 25.56 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About SEPN
Septerna is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by its proprietary Native Complex Platform. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Our lead product candidate, SEP-786, is a clinica... [Read more]
News
Septerna valued at $970 million as shares rise nearly 31% in Nasdaq debut
Septerna's shares rose about 31% in their market debut on Friday, giving the Goldman Sachs-backed biotech firm a valuation of $970 million.
Septerna Prices Upsized Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral smal...
Goldman-backed drug developer Septerna targets $743 mln valuation in upsized US IPO
Goldman Sachs-backed drug developer Septerna said on Thursday it was seeking a valuation of $743.1 million in its upsized initial public offering in the United States.
Biotech Septerna aims to raise up to $186 million in US IPO
Biotechnology company Septerna said on Monday it is aiming to raise up to $186 million in its initial public offering in the United States.
Septerna Pursues $100 Million IPO For Endocrine And Metabolic Drug Pipeline
Septerna, Inc. aims to raise $100 million in an IPO to advance its clinical-stage biopharma treatments for endocrine diseases, with SEP-786 in Phase 1 trials. The hypoparathyroidism treatment market i...
Septerna IPO Registration Document (S-1)
Septerna has filed to go public with an IPO on the NASDAQ.